Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30067027HIVENSG00000164543.7protein_codingSTK17ANoNo9263Q9UEE5
TVIS30067028HIVENSG00000164543.7protein_codingSTK17ANoNo9263Q9UEE5
TVIS30067029HIVENSG00000164543.7protein_codingSTK17ANoNo9263Q9UEE5
TVIS30067030HIVENSG00000164543.7protein_codingSTK17ANoNo9263Q9UEE5
TVIS30067031HIVENSG00000164543.7protein_codingSTK17ANoNo9263Q9UEE5
TVIS30067032HIVENSG00000164543.7protein_codingSTK17ANoNo9263Q9UEE5
TVIS30067033HIVENSG00000164543.7protein_codingSTK17ANoNo9263Q9UEE5
TVIS30067034HIVENSG00000164543.7protein_codingSTK17ANoNo9263Q9UEE5
TVIS30067035HIVENSG00000164543.7protein_codingSTK17ANoNo9263Q9UEE5
TVIS30067036HIVENSG00000164543.7protein_codingSTK17ANoNo9263Q9UEE5
TCGA Plot Options
Drug Information
GeneSTK17A
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009543
UniProt IDQ9UEE5
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830